State Health and Value Strategies (SHVS), in partnership with Manatt Health, Georgetown’s Center on Health Insurance Reforms (CHIR), State Health Access Data Assistance Center (SHADAC), Bailit Health, and GMMB developed this resource page to serve as an accessible “one-stop” source of COVID-19 information for states. This resource is designed to support states seeking to make coverage and essential services available to all of their residents, especially high-risk and vulnerable people, during the COVID-19 pandemic. SHVS will update this page frequently with new resources as they become available.
| If you have materials you are willing to share with other states through this page, or if there are topics of particular concern that you would like addressed, please contact SHVS. |
This FAQ answers common provider questions regarding the provision of methadone and buprenorphin, including through the use of telehealth, for the treatment of opioid disorder during the COVID-19 crisis.
North Carolina website cataloging guidance on telehealth expansion during COVID-19, including recent policies related to enhanced behavioral health services, optometry services, postpartum care visits, and even self-measured blood pressure monitoring.
Medicaid memo to providers summarizing changes to program requirements, including expansion of telehealth coverage, provider licensure, and prior authorization for services, during the COVID-19 crisis. Content on behavioral health was updated in a subsequent memo.
This memo clarifies a section of the earlier Medicaid provider memo on flexibilities offered to providers of behavioral health and addiction and recovery treatment.
Guidance from New York State Office of Mental Health on adult Continuing Day Treatment (CDT) program expectations, changes in documentation requirements during the disaster emergency period, and reduction or elimination of minimum billing requirements.
Guidance from New York State Office of Mental Health on Assertive Communty Treatment (ACT) program expectations, changes in documentation requirements during the disaster emergency period, and the reduction or elimination of minimum billing requirements.
FAQs include HRSA’s guidance for health centers related to COVID-19, which is updated on an ongoing basis. 4/7 updates to FAQs include guidance on infection control/prevention for health centers, health center obligations for paid sick leave/other benefits for staff, liability protections for volunteer providers, permissible adjustments to operating hours, telehealth, and scope of practice.
CMS released an interim final rule with comment period that proposes several changes to the Medicaid and Medicare programs. For the Medicaid program, the rule amends health home regulations by allowing other licensed practitioners to order home health services, without physician sign-off.
This comprehensive resource page on COVID-19 guidance includes multiple funding opportunities to support telehealth for behavioral health services, naloxone distribution, and Opioid Treatment Program facilities.
This letter to behavioral health managed care plans outlines efforts from NC DHHS to provide flexible funding to stabilize providers and respond to the changing needs of consumers.
This guidance allows practitioners further flexibility in prescribing and dispensing buprenorphine to new and existing patients with opioid use disorder via telephone without examination in person or via telemedicine.
This guidance allows OTPs to make “door stop” deliveries for medications for opioid use disorder in a lock-box for patients under quarantine.
This guidance allows OTPs to make “door stop” deliveries for medications for opioid use disorder in a lock-box for patients under quarantine.
This guidance allows prescribers and practitoners to issue time limited prescriptions of schedule II drugs via oral communication (e.g., telephone) under limited circumstances.
This guidance allows practitioners to dispense schedule II-IV drugs (including methadone, buprenorphine and opioids) not only in their home states but also in states with which their home stateshave reciprocity.
This order allows pharmacists and pharmacy interns to administer methadone and buprenorphine for the treatment of opioid use disorder.
This memo provides interim guidance to assist Opioid Treatment Programs with providing medications to patients, aligning state policy with federal take home exceptions of 14 and 28 days.
This FAQ provides guidance to narcotic treatment programs, including information on services that may be provided by telehealth.
MA developed a managed care plan bulletin that outlines requirement’s for coverage and billing related to COVID-19.
This FAQ includes guidance for behavioral health providers, partners, and the greater community to develop coordinated prevention and response plans for COVID-19.
This page includes guidance and a template for COVID-19 1115 waiver demonstrations.